Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2020 Dec 4;22(Suppl 3):iii295–iii296. doi: 10.1093/neuonc/noaa222.092

DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW

Margot A Lazow 1, Christine Fuller 1, Adam Lane 1, Mariko D DeWire-Schottmiller 1, Pratiti Bandopadhayay 2, Ute Bartels 3, Eric Bouffet 3, Sylvia Cheng 4, Kenneth J Cohen 5, Tabitha M Cooney 6, Scott L Coven 7, Hetal Dholaria 8, Blanca Diez 9, Kathleen Dorris 10, Motasem El-Ayadi 11, Ayman El-Sheikh 12, Paul G Fisher 13, Mercedes Garcia Lombardi 14, Robert J Greiner 15, Stewart Goldman 16, Nicholas Gottardo 8, Sridharan Gururangan 17, Jordan R Hansford 18, Tim Hassall 19, Cynthia Hawkins 3, Lindsay Kilburn 20, Carl J Koschmann 21, Sarah E Leary 22, Jie Ma 23, Jane E Minturn 24, Michelle Monje-Deisseroth 13, Roger J Packer 20, Yvan Samson 25, Eric S Sandler 26, Gustavo Sevlever 9, Christopher Tinkle 27, Karen Tsui 28, Lars M Wagner 29, Mohamed Zaghloul 11, David S Ziegler 30, Brooklyn Chaney 1, Katie Black 1, Anthony Asher 1, Rachid Drissi 1, Maryam Fouladi 1, Blaise V Jones 1, James L Leach 1
PMCID: PMC7715769

Abstract

INTRODUCTION

The role of diagnostic biopsy in diffuse intrinsic pontine glioma (DIPG) remains in question. Distinguishing radiographically between DIPG and other pontine tumors with more favorable prognosis and different therapy is critically important.

METHODS

Cases submitted to the International DIPG registry with histopathologic data were analyzed. Central imaging review was performed by two neuro-radiologists; all cases with imaging features or histopathology suggestive of alternative diagnoses were re-reviewed. Imaging features suggestive of alternative diagnoses included non-pontine origin, <50% pontine involvement (without typical DIPG pattern on follow-up), focally exophytic morphology, sharply-defined margins, or marked diffusion restriction throughout.

RESULTS

Among 297 patients with pathology from biopsy and/or autopsy available, 27 (9%) had histologic diagnoses not consistent with DIPG, commonly embryonal tumors (n=9) and pilocytic astrocytomas (n=11). 163 patients had diagnostic MRI available for central neuroimaging review. Among 81 patients classified as characteristic of DIPG, 80 (99%) had histopathology consistent with DIPG (diffuse midline glioma, H3K27M-mutant, glioblastoma, anaplastic astrocytoma, diffuse astrocytoma). Among 63 patients classified as likely DIPG, but with unusual imaging features, 59 (94%) had histopathology consistent with DIPG. 19 patients had imaging features suggestive of another diagnosis, including 13 with non-pontine tumor origin; the remaining 6 all had histopathology not consistent with DIPG. Association between central imaging review and histopathology was significant (p<0.001).

CONCLUSIONS

The important role and accuracy of central neuroimaging review in diagnosing or excluding DIPG is demonstrated. In patients with pontine tumors for which DIPG is felt unlikely radiographically, biopsy may be considered to guide diagnosis and treatment.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES